Revolution Medicines, Inc.

Equities

Market Closed - Nasdaq Other stock markets 20:00:00 09/03/2026 GMT			5-day change	1st Jan Change
99.79 ^USD	+1.41%		-1.80%	+25.29%

03-04	Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing	MT
03-03	Revolution Medicines, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM

Published on 02/11/2026 at 03:35 pm GMT

S&P Capital IQ

Presenter Speech
Michael Schmidt (Analysts)

All right. So good morning. My name is Michael Schmidt, Senior Biotech Analyst with Guggenheim. And it's my great pleasure to welcome Mark Goldsmith,

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

03-04	Revolution Medicines Insider Sold Shares Worth $3,644,354, According to a Recent SEC Filing	MT
03-03	Revolution Medicines, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM
02-27	Revolution's Daraxonrasib has 'Blockbuster' Potential, UBS Says	MT
02-27	UBS Adjusts Revolution Medicines Price Target to $145 From $71, Maintains Buy Rating	MT
02-27	Truist Adjusts Price Target on Revolution Medicines to $116 From $99, Maintains Buy Rating	MT
02-27	Truist Raises Price Target on Revolution Medicines to $116 From $99, Keeps Buy Rating	MT
02-26	The Bar Just Moved Higher
02-26	Mizuho Trims Price Target on Revolution Medicines to $140 From $143, Keeps Outperform Rating	MT
02-26	Revolution Medicines, Inc., Q4 2025 Earnings Call, Feb 25, 2026
02-26	Revolution Medicines Inc files for common stock offering of up to $1.0 billion	RE
02-25	Revolution Medicines Q4 Loss Widens	MT
02-25	Earnings Flash (RVMD) Revolution Medicines Posts Q4 Loss $1.86, vs. FactSet Est of $1.58 Loss	MT
02-25	Revolution Medicines, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-11	Revolution Medicines, Inc. Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2026, Feb-11-2026 09:30 AM
01-29	Revolution Medicines Says First Patient Dosed in Solid Tumor Trial	MT